RxDoctor Payments Data

Emily McCullar, MD

Family Medicine · Rockwall, TXNPI 1982085544

Payments from drug & device makers

$8,115in general payments, 2019–2025

Across 401 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$798
  • GSK$689
  • Astellas Pharma US Inc$614
  • Lilly USA, LLC$551
  • Amgen$537
  • Novo Nordisk$493
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$8,01699%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,115 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$112,947
Medicare patients
288
Services billed
1,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$110,127
JardianceEmpagliflozin72$108,789
OzempicSemaglutide70$85,363
MounjaroTirzepatide49$68,950
EliquisApixaban47$60,080
FarxigaDapagliflozin Propanediol37$51,224
TrulicityDulaglutide28$42,516
RybelsusSemaglutide17$36,924
XareltoRivaroxaban22$32,901
Repatha SureclickEvolocumab27$24,774
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$23,892
MyrbetriqMirabegron23$19,811
JanuviaSitagliptin Phosphate14$16,061
WegovySemaglutide12$15,768
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$10,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$493$138,05699 claims
GSKTrelegy Ellipta, Breo Ellipta$689$117,81485 claims
Lilly USA, LLCMounjaro, Trulicity$551$111,46677 claims
Boehringer IngelheimJardiance$39$108,78972 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$342$81,20681 claims
PfizerEliquis$329$60,08047 claims
Johnson & JohnsonXarelto$23$32,90122 claims
Astellas Pharma US IncMyrbetriq$614$19,81123 claims
MerckJanuvia$168$16,06114 claims
AbbVieNamzaric$798$6,86612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →